Japan’s health ministry approved a slew of new medicines on September 25 including multiple “first of its kind” products, among them being GlaxoSmithKline’s respiratory syncytial virus (RSV) vaccine Arexvy as well as Eisai’s Alzheimer’s therapy Leqembi (lecanemab).Arexvy became the first…
HOME > REGULATORY
REGULATORY
- Abortion Pill Mefeego’s Japan Panel Review Rescheduled for April 21
April 18, 2023
- Expert Panel Proposal to Be Compiled at May-End: MHLW Official
April 18, 2023
- Relief Claims OK’ed for 12 More Deaths Possibly Linked to COVID Jabs
April 18, 2023
- Comprehensive Review of COVID Budgets Necessary: MOF Panel Chair
April 17, 2023
- Japan to Set Out Measures Against Hay Fever, Promote Curative Therapy
April 17, 2023
- Number of Mpox Cases Totals 109 in Japan: MHLW
April 17, 2023
- Japan to Map Out Substantive Policy to Solve Pharma Industry Issues: Minister
April 14, 2023
- Lower House Clears Bill to Amend Next-Gen Medical Infrastructure Law
April 14, 2023
- LDP Pharma Study Group to Draw Up Resolution in May before Honebuto Paper
April 13, 2023
- Lawmakers Split 50/50 on Abortion Pill, No Conclusion at LDP Panel
April 13, 2023
- Ultomiris’ NMOSD Nod Up for Advisory Panel Review on April 26
April 13, 2023
- Mpox Cases Top 100 in Japan, 10 New Patients Confirmed
April 13, 2023
- Pandemic Response Agency to Be Set Up as Early as September: Minister Goto
April 12, 2023
- Japan Aims to Cut Use of IV Carbapenem Antibiotics by 20%: AMR Action Plan
April 11, 2023
- LDP Project Team Calls for Price Maintenance During Patent Period and Rethink of Off-Year Cuts
April 11, 2023
- Skyrizi’s Palmoplantar Pustulosis Use on PAFSC Agenda on April 24
April 11, 2023
- China Envoy Says Spying Allegations of Astellas Employee Becoming Certain
April 10, 2023
- 9-Valent HPV Vaccine Program Poses Opportunity to Boost Inoculation Rate: LDP Lawmaker
April 7, 2023
- Japan Needs Guidelines on Conditional Approval for Regenerative Medicines: Lawmakers
April 7, 2023
- Tokyo Likely to See Next COVID Spike around First Half of May: Experts
April 7, 2023
ページ
“Time is the scarcest resource, and unless it is managed, nothing else can be managed.” - Peter DruckerSearching for the right candidate takes time… but how much time?The last thing you want is to waste time searching for the wrong…
A doctor member of the Central Social Insurance Medical Council (Chuikyo) on September 20 traded barbs with pharma leaders over…
The Ministry of Health, Labor and Welfare (MHLW) on September 19 proposed restructuring the Japanese generic industry by restricting the…
The Ministry of Health, Labor and Welfare (MHLW) plans to no longer require the implementation of additional PI clinical studies…
In the run-up to FY2024 budget requests this summer, there were growing hopes in the pharmaceutical industry that the government's de-facto cap on increases in social security spending would finally be lifted. That did not happen, despite strong calls from…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…